Address
120 Presidential Way
Woburn, DE 01801
United States of America (the)
Phone
781-245-1325
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
92
First IPO Date
October 29, 2021
| Name | Title | Pay | Year Born |
| Hermann Luebbert | Chief Executive Officer, President & Chairman | 687,482 | 1956 |
| George Jones | Chief Commercial Officer | 275,184 | 1973 |
| Eugene Frederick Leffler | Chief Financial Officer | 461,333 | 1985 |
| Jon Lyons | Vice President of Scientific & Medical Affairs | 0 | N/A |
| Erica F. Gates | VP of Finance & Principal Accounting Officer | 0 | N/A |
| Samantha Widdicombe | Senior Vice President of Sales & Strategic Accounts | 0 | N/A |
| Daniel Hakansson | Senior Corporate Counsel | 0 | N/A |
Biofrontera Inc. is a biopharmaceutical firm specializing in the commercialization of pharmaceutical solutions for skin-related ailments across the United States. Its product lineup features Ameluz, a prescription drug employed with the BF-RhodoLED lamp series for photodynamic therapy. This treatment is designed for both localized and broader area management of mild-to-moderate actinic keratosis on the face and scalp. Additionally, the company offers Xepi, a topical, non-fluorinated quinolone that functions by inhibiting bacterial growth to treat impetigo. Established in 2015, Biofrontera Inc. is headquartered in Woburn, Massachusetts.